Iconovo initiates structured sales process for ICOpre
Iconovo is currently in negotiations with global pharmaceutical companies regarding the company’s latest developed inhaler platform, ICOpre. The company has engaged the global investment bank Stifel to maximize the value and structure the outlicensing process. BioStock contacted Iconovo’s CEO Johan Wäborg to find out more.
Iconovo has developed four inhaler platforms for the developing of novel pharmaceuticals and vaccines, as well as generic versions of blockbuster inhalation drugs. One of the generic projects is ICOpre, a pre-metered inhaler with the same features as GSK’s well-known inhaler. ICOpre can be loaded with three different drug substances and has a precise dose counter just like Ellipta.
Read article from BioStock here